CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
flibanserin 100 mg dose every eveningdrug
Likely dose
flibanserin 100 mg dose every eveningfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01188603
NCT01188603Phase 1Completed

Evaluation of Single Dose and Steady State Pharmacokinetics of Flibanserin Postmenopausal Women With Hypoactive Sexual Desire Disorder

Sprout Pharmaceuticals, Inc·interventional·Posted Aug 25, 2010·Updated May 21, 2014

In Brief

A Phase 1 clinical trial evaluating flibanserin 100 mg dose every evening for Sexual Dysfunctions, Psychological. Completed, enrolled 24 participants across 4 sites.

Detailed Summary

This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 25, 2010
Enrollment StartJul 1, 2010
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.9 years ago

Interventions

flibanserin 100 mg dose every eveningdrug

all subjects receive flibanserin